‘Vaccines Even More Harmful Than Severe COVID’
I took two doses of Pfizer’s mRNA [COVID] vaccine unaware, at the time, that it was, in fact, a prophylactic gene therapy product and unlike any traditional vaccine. I’m a grieving vaccine injured doctor. I’ve been diagnosed with a persistent autoimmune condition related to loss of bifidobacteria in my gut, and advanced blood tests suggested […]
FDA Panel Backs mFlusiva mRNA Flu Shot for Elderly
Despite a number of significant limitations in the available safety and efficacy data for licensure review of Moderna, Inc.’s new mRNA influenza biologic mFlusiva, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee ((VRBPAC) voted on June 18, 2026 to recommend fast-tracked licensure of the first mRNA product to target […]
FDA Set to Review Moderna’s mFlusiva mRNA Flu Shot
An mRNA (messenger ribonucleic acid) influenza biologic developed by Moderna, Inc. is scheduled to be reviewed today by a U.S. Food and Drug Administration (FDA) advisory panel. The Vaccines and Related Biological Products Advisory Committee ((VRBPAC) will evaluate data on Moderna’s mFlusiva (formerly known as mRNA-1010) to determine if the product provides superior relative vaccine […]
Scientists Creating mRNA Biologics with Added Aluminum Adjuvant
Scientists at Boston Children’s Hospital in Massachusetts have developed an experimental mRNA biologic technology that they say produced longer-lasting immune responses in animal studies without the use of additional booster shots. The 2026 study was published in Nature Immunology.1 The research looked at a challenge in mRNA technology on how to make protection last longer […]
Ebola Bundibugyo Vaccines in Development Four Months Before Outbreak
An Ebola outbreak in the Ituri province of the Democratic Republic of the Congo (DRC) was confirmed by the Africa Centers for Disease Control and Prevention (Africa CDC) on May 15, 2026. Through laboratory analysis, health officials confirmed that the outbreak is caused by the Bundibugyo ebola strain, for which there is no vaccine currently […]
Public-Private Partnership Builds Africa’s First Multi-Vaccine Production Plant
European investors have announced their partnership with South African biopharmaceutical company The Biovac Institute in building Africa’s first end-to-end multi-vaccine manufacturing facility in South Africa. Biovac projects to annually produce tens of millions of doses of vaccines for cholera, polio, and pneumonia. The plant will be the continent’s first end-to-end vaccine manufacturing plant, and the […]